Evaluation of the safety and efficacy of the vaccine PB-116 in the control of porcine pleuropneumonia caused by Actinobacillus pleuropneumoniae
EU record number:
Company / Sponsor:
Laboratorios Hipra S.A.
Active immunisation of fattening pigs for the prevention of the mortality, clinical signs and pulmonary lesions of the respiratory processes produced by Actinobacillus pleuropneumoniae
no new genes but deletion of a segment of gene A from which depends the haemolytic activity of the pathogen
Method of transfer of nucleic acid of interest:
Actinobacillus pleuropneumoniae strain HP-3179
Route of administration:
Locations in Belgium:
To be defined
Nr of subjects:
2400 pigs but about 1200 in Belgium
to be defined
Type of procedure:
Deliberate release only
Information for the public
Public information presented according to the provisions of Directive 2001/18/EC
Information related to the decision procedure
1 August 2012: The Federal Ministers gives a final decision (positive with conditions) for this trial.
16 April 2012: The Biosafety Advisory Council issues a positive advice (with conditions) for this trial.